folder

Systematic pharmacological screens uncover novel pathways involved in cerebral cavernous malformations

Authors

  • C. Otten
  • J. Knox
  • G. Boulday
  • M. Eymery
  • M. Haniszewski
  • M. Neuenschwander
  • S. Radetzki
  • I. Vogt
  • K. Hähn
  • C. De Luca
  • C. Cardoso
  • S. Hamad
  • C. Igual Gil
  • P. Roy
  • C. Albiges‐Rizo
  • E. Faurobert
  • J.P. von Kries
  • M. Campillos
  • E. Tournier‐Lasserve
  • W.B. Derry
  • S. Abdelilah-Seyfried

Journal

  • EMBO Molecular Medicine

Citation

  • EMBO Mol Med 10 (10): e9155

Abstract

  • Cerebral cavernous malformations (CCMs) are vascular lesions in the central nervous system causing strokes and seizures which currently can only be treated through neurosurgery. The disease arises through changes in the regulatory networks of endothelial cells that must be comprehensively understood to develop alternative, non-invasive pharmacological therapies. Here, we present the results of several unbiased small-molecule suppression screens in which we applied a total of 5,268 unique substances to CCM mutant worm, zebrafish, mouse, or human endothelial cells. We used a systems biology-based target prediction tool to integrate the results with the whole-transcriptome profile of zebrafish CCM2 mutants, revealing signaling pathways relevant to the disease and potential targets for small-molecule-based therapies. We found indirubin-3-monoxime to alleviate the lesion burden in murine preclinical models of CCM2 and CCM3 and suppress the loss-of-CCM phenotypes in human endothelial cells. Our multi-organism-based approach reveals new components of the CCM regulatory network and foreshadows novel small-molecule-based therapeutic applications for suppressing this devastating disease in patients.


DOI

doi:10.15252/emmm.201809155